Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
4.920
-1.230 (-20.00%)
May 13, 2025, 4:00 PM - Market closed
Karyopharm Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 38.78 | 62.48 | 52.23 | 135.19 | 190.46 | 85.92 | Upgrade
|
| Short-Term Investments | 31.16 | 46.24 | 139.21 | 142.78 | 38.16 | 163.32 | Upgrade
|
| Cash & Short-Term Investments | 69.94 | 108.71 | 191.44 | 277.97 | 228.62 | 249.24 | Upgrade
|
| Cash Growth | -52.93% | -43.21% | -31.13% | 21.59% | -8.28% | -4.85% | Upgrade
|
| Receivables | 35.24 | 30.77 | 27.96 | 54.89 | 23.9 | 12.88 | Upgrade
|
| Inventory | 4.77 | 4.74 | 3.04 | 4.22 | 4.11 | 2.64 | Upgrade
|
| Prepaid Expenses | 10.29 | 12.25 | 10.81 | 12.02 | 12.64 | 9.29 | Upgrade
|
| Restricted Cash | - | 0.03 | 0.66 | 1.06 | 6.35 | 2.48 | Upgrade
|
| Total Current Assets | 120.24 | 156.49 | 233.92 | 350.16 | 275.61 | 276.53 | Upgrade
|
| Property, Plant & Equipment | 5.8 | 6.28 | 4.88 | 7.38 | 9.56 | 11.58 | Upgrade
|
| Long-Term Investments | - | - | - | - | - | 24.22 | Upgrade
|
| Long-Term Accounts Receivable | - | - | - | - | 19.51 | - | Upgrade
|
| Other Long-Term Assets | 1.67 | 1.64 | 1.64 | 0.63 | 0.64 | 0.72 | Upgrade
|
| Total Assets | 127.71 | 164.42 | 240.44 | 358.17 | 305.31 | 313.05 | Upgrade
|
| Accounts Payable | 5.87 | 5.11 | 3.12 | 2.77 | 1.6 | 4.45 | Upgrade
|
| Accrued Expenses | 57.17 | 60.65 | 61.39 | 58.42 | 69.12 | 52.93 | Upgrade
|
| Short-Term Debt | 24.46 | 24.43 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 0.93 | 0.44 | 3.31 | 2.87 | 2.32 | 1.92 | Upgrade
|
| Current Unearned Revenue | - | - | - | - | - | 0.3 | Upgrade
|
| Other Current Liabilities | 1.94 | 1.64 | 1.65 | 1.85 | 0.68 | 0.61 | Upgrade
|
| Total Current Liabilities | 90.37 | 92.26 | 69.48 | 65.91 | 73.72 | 60.2 | Upgrade
|
| Long-Term Debt | 228.33 | 236.45 | 303.4 | 302.82 | 302.29 | 191.02 | Upgrade
|
| Long-Term Leases | 6.49 | 6.71 | 2.79 | 6.1 | 8.97 | 11.29 | Upgrade
|
| Other Long-Term Liabilities | 8.41 | 15.01 | 0.98 | - | - | - | Upgrade
|
| Total Liabilities | 333.6 | 350.44 | 376.64 | 374.83 | 384.98 | 262.5 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 1,381 | 1,378 | 1,351 | 1,328 | 1,099 | 1,120 | Upgrade
|
| Retained Earnings | -1,587 | -1,563 | -1,487 | -1,344 | -1,179 | -1,070 | Upgrade
|
| Comprehensive Income & Other | -0.32 | -0.36 | -0.16 | -0.64 | 0.19 | 0.52 | Upgrade
|
| Shareholders' Equity | -205.88 | -186.02 | -136.21 | -16.66 | -79.67 | 50.55 | Upgrade
|
| Total Liabilities & Equity | 127.71 | 164.42 | 240.44 | 358.17 | 305.31 | 313.05 | Upgrade
|
| Total Debt | 260.2 | 268.02 | 309.5 | 311.79 | 313.58 | 204.22 | Upgrade
|
| Net Cash (Debt) | -190.26 | -159.31 | -118.05 | -33.83 | -84.96 | 45.02 | Upgrade
|
| Net Cash Growth | - | - | - | - | - | -29.28% | Upgrade
|
| Net Cash Per Share | -22.88 | -18.84 | -15.50 | -6.20 | -16.94 | 9.37 | Upgrade
|
| Filing Date Shares Outstanding | 8.64 | 8.42 | 7.67 | 7.56 | 5.28 | 4.98 | Upgrade
|
| Total Common Shares Outstanding | 8.57 | 8.41 | 7.66 | 7.55 | 5.05 | 4.93 | Upgrade
|
| Working Capital | 29.87 | 64.23 | 164.44 | 284.25 | 201.89 | 216.33 | Upgrade
|
| Book Value Per Share | -24.03 | -22.11 | -17.78 | -2.21 | -15.78 | 10.26 | Upgrade
|
| Tangible Book Value | -205.88 | -186.02 | -136.21 | -16.66 | -79.67 | 50.55 | Upgrade
|
| Tangible Book Value Per Share | -24.03 | -22.11 | -17.78 | -2.21 | -15.78 | 10.26 | Upgrade
|
| Machinery | - | 2.21 | 2.29 | 2.33 | 2.25 | 1.97 | Upgrade
|
| Leasehold Improvements | - | 4.88 | 4.88 | 5.45 | 5.45 | 5.44 | Upgrade
|
Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.